Specialty pharmacy expands access to an innovative, steroid-free treatment NEW PROVIDENCE, NJ, UNITED STATES, March 3, 2025 /EINPresswire / -- ...

Q4 2024 Earnings Call Transcript February 27, 2025 Verona Pharma plc misses on earnings expectations. Reported EPS is $-0.4 ...

belief that Ohtuvayre's bronchodilator and non-steroidal anti-inflammatory activity can re-define the COPD treatment paradigm." The encouraging sales figures come at a time when treatment options ...

Many have heard about "Good Night Lights" for patients at Hasbro Children's Hospital, and recently, a Warwick boy was the ...

Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus ...

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1The primary endpoint ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch –– Launched Niktimvo™ (axatilimab-csfr) in the U.S.

Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today’s call is being recorded.

Shorla Oncology (?Shorla'), a U.S.-Ireland specialty pharmaceutical company, today announced the launch of a dedicated sales force and market access teams and the commercial availability of IMKELDI, ...

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch - - Launched Niktimvo (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte - - sNDA ...

Chronic obstructive pulmonary disease (COPD) is among the most common breathing conditions. It's the result of damaged lung ...